When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
Install
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
The odds
62%chance▼ 1
How the odds have moved
Yes: 47% on Oct 20, 62% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Why it moved
- Oct 31, 9 PM ET45% → 52%
- Oct 27, 10 PM ET52% → 45%
The biggest swings over the chart's period, each with the headlines about the market's subject published in the hours before it. News and odds moving together is not proof one caused the other.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 62% | ▼ 1 | 59¢ | 65¢ | $1.54 | 11.3K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Summit Therapeutics, Ivonescimab
Search ›- Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on MondayPosted by Mitch Edgeman on Nov 4th, 2026 Read Our Latest Stock Analysis on Summit Therapeutics Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of…
- FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This WeekThe U.S. Food and Drug Administration (FDA) is set to decide on three major drug applications this week, covering treatments for lung cancer, heart disease, and acute agitation associated with psychiatric disorders In what could…
- Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature MedicineThe study demonstrated that neoadjuvant ivonescimab in combination with chemotherapy produced high rates of pathological response in patients with resectable NSCLC. Among patients who underwent surgery, the major pathological response…
- Ivonescimab Achieves 50.7% pCR Rate in Phase II Perioperative NSCLC StudyJon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Ivonescimab Achieves 50.7% pCR Rate in Phase II Perioperative…
- Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract CancerPublished on 11/04/2026 at 11:21 pm EST The HARMONi-GI1 results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO Presidential Symposium in October 2026. HARMONi-GI1 is the first Phase III trial in BTC to show…
- Akeso's ivonescimab plus chemo yields 70% pathological response in resectable NSCLCAllSci Akeso (HKEX: 9926.HK) reported in Nature Medicine that perioperative ivonescimab, its PD-1/VEGF bispecific antibody, plus chemotherapy reached a 70.1% major pathological response (MPR) rate in resectable non-small cell lung cancer…
- Narrative Review Examines Dual Cardiovascular Toxicities of Bispecific Antibody IvonescimabA narrative review evaluates the dual vascular and immune-mediated cardiotoxicity profile of the bispecific antibody ivonescimab and proposes a risk-stratified cardio-oncology surveillance framework.
- SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in FocusSummit Therapeutics SMMT incurred a third-quarter 2026 loss per share of 26 cents, narrower than the Zacks Consensus Estimate of a loss of 28 cents per share. In the year-ago period, the company had recorded a loss of 31 cents per share…
- Evercore ISI Sticks to Their Buy Rating for Cytokinetics (CYTK)In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Cytokinetics, with a price target of $100.00. Kasimov covers the Healthcare sector, focusing on stocks such as Cytokinetics, Revolution Medicines, and…
- FDA Clinical Investigations: New Guidance on Electronic SystemsOn October 2, 2024, the U.S. Food and Drug Administration (FDA) released guidance in a question and answer format regarding the use of electronic systems, electronic records, and electronic signatures in clinical investigations of medical…
- Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia, agreed 19 out of 22 panel members at…
- FDA investigates Novartis gene therapy link to tumours in childrenThe US Food and Drug Administration (FDA) has launched an investigation into a Novartis gene therapy for potential links to tumour growth in patients. The Swiss drug maker disclosed on Friday that two children who had received Zolgensma…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 5 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions